Update: Solira's Foundayo pricing is confirmed, from £79.99 per 30-day supply, plus £2.99 delivery. See the full Foundayo price list.
On 10 August 2026, the MHRA approved Foundayo (orforglipron), making the UK the first country in Europe to license Eli Lilly's once daily weight loss tablet.
What exactly was approved?
The MHRA licensed Foundayo for weight management in adults with a BMI of 30 or above, or a BMI of 27 to 30 alongside at least one weight related condition such as high blood pressure or type 2 diabetes. Unusually for a weight loss licence, it also covers blood sugar control in adults with type 2 diabetes whose current treatment is not working well enough. The US FDA approved the same medicine in April 2026, so the UK decision follows several months of real world American use.
The Foundayo timeline
Orforglipron was approved in the United States, giving several months of real world use before the UK decision.
The UK became the first country in Europe to license Foundayo, for weight management and for blood sugar control in type 2 diabetes.
Ordering opened at Solira. You can get Foundayo after a consultation reviewed by one of our pharmacists.
About FoundayoNHS funding is a separate decision made by NICE. Until NICE recommends it, Foundayo is a private treatment.
Why this tablet is different
There is already one GLP-1 weight loss tablet in the UK, the Wegovy tablet, which launched in June. But the Wegovy tablet is a peptide, so it comes with strict rules: an empty stomach, no more than 120ml of water, and a 30 minute wait before eating, drinking, or taking other medicines. Foundayo is a small-molecule medicine rather than a peptide, and food makes no clinically relevant difference to how much of it is absorbed, so it can be taken at any time of day, with or without food or water. The UK product information for Wegovy tablets estimates that only about 1 to 2% of an oral semaglutide dose is absorbed and that eating or drinking within 30 minutes reduces this, which is why those tablets are taken on an empty stomach. For anyone whose mornings do not suit a fasting routine, that flexibility is the headline.
How well does it work?
In the ATTAIN-1 trial, published in the New England Journal of Medicine, more than 3,100 adults took orforglipron or placebo for 72 weeks. Counting everyone who started treatment, people on the doses matching Foundayo 5.5mg, 9mg and 17.2mg lost an average of 7.5%, 8.4% and 11.2% of their body weight over 72 weeks, compared with 2.1% on placebo (ATTAIN-1, NEJM 2025). In trials lasting 64 to 72 weeks, average weight loss counting everyone who started was about 11% with Foundayo at its highest dose, about 14% with Wegovy tablets, about 15% with Wegovy 2.4mg, about 19% with Wegovy 7.2mg and about 21% with Mounjaro 15mg. These were separate trials in different groups of people, so the figures are not a direct comparison. Individual results vary. ATTAIN-1 also recorded improvements in waist size, cholesterol, and blood pressure. For a closer look at the two tablets side by side, read our Foundayo vs Wegovy tablets comparison. We have also published our confirmed UK pricing for every dose.
Dosing and side effects
Foundayo starts at 0.8mg once daily and steps up through 2.5mg, 5.5mg, 9mg, and 14.5mg to a maximum of 17.2mg, with at least a month at each level. Side effects are the familiar GLP-1 pattern, mainly nausea, constipation, diarrhoea, and stomach discomfort, worst in the first weeks and after dose increases, and easing over time for most people.
When can you actually get it?
Now. Foundayo is available from Solira following a free weight-management consultation reviewed by our pharmacist, with pricing confirmed for every dose. It is not funded on the NHS for weight management, and NICE will assess it separately.